| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Yingbin Zhou CEO | XSHE Exchange | CNE100000JZ3 ISIN |
| CN Country | 1,225 Employees | 29 May 2026 Last Dividend | 10 May 2017 Last Split | 8 Jan 2010 IPO Date |
Shanghai Kaibao Pharmaceutical CO., Ltd is a leading entity in the realm of Chinese medicine, concentrating on the research, development, production, and commercialization of modern Chinese medical solutions. Founded in the year 2000 and headquartered in Shanghai, China, the company has established a robust presence in the Chinese healthcare market. Its commitment to innovation and quality has facilitated the provision of effective treatments for a variety of conditions, solidifying its status as a crucial player in the pharmaceutical industry within China.
Tanreqing Injection - This product is primarily used in the treatment of pneumonia, acute and chronic bronchitis, and upper respiratory tract infections. It reflects Shanghai Kaibao Pharmaceutical's expertise in creating solutions that target respiratory conditions effectively.
Tanreqing Capsules - Designed for clearing heat, detoxifying the body, and removing phlegm, these capsules represent the company's dedication to leveraging traditional Chinese medicine principles for modern healthcare needs.
Tiopronin for Injection - A testament to the company's commitment to liver health, this product aims at improving the liver function in patients suffering from various forms of acute and chronic hepatitis.
Tiopronin Enteric-coated Tablets - Serving as an adjuvant treatment for chronic hepatitis, these tablets highlight the company's focus on developing pharmaceuticals that support liver health and function.
Xiongdan Dropping Pills - This product is developed to clear heat, calm the liver, and improve eyesight, underscoring Shanghai Kaibao Pharmaceutical's utilization of traditional Chinese medicinal knowledge to address a broad spectrum of health concerns.